Compare Angi Inc (ANGI) vs ClearPoint Neuro Inc (CLPT) Price & Performance

ANGI trades at $6.24, down 1.89% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue of $1.03B in 2025 and net income of $43.83M, representing a 4.25% margin. Valuation metrics appear attractive with P/E of 14.85 and P/S of 0.27. Recent earnings showed a beat in Q1 2026 but misses in previous quarters, while analyst consensus price target sits at $9.20 with 33% buy ratings.

The stock presents a mixed outlook with attractive valuation multiples offset by declining revenue trends and ongoing legal investigations. Upside potential exists if the company's AI transition strategy succeeds, but risks include deteriorating core business metrics and multiple fraud investigations that could pressure shareholder value in the near term.

ClearPoint Neuro (CLPT) trades at $17.50, down 2.13% on the day, with a bullish technical signal from moving averages despite recent earnings misses. The company reported record Q1 2026 revenue of $41M with 43% growth but continues to post significant net losses, reflected in a negative net income margin of -71.57%. Recent FDA clearance for its Velocity Alpha surgical drill and a new partnership in South Korea highlight ongoing business development efforts.

The investment case hinges on CLPT's positioning in the gene therapy enabling space, with 100% analyst buy ratings supporting long-term growth potential. However, persistent cash burn, regulatory dependencies on partner therapies like AMT-130, and execution risks present substantial challenges. Investors face high volatility given the speculative nature of its growth trajectory against current profitability concerns.